Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
mercoledì, ottobre 28
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Moleculin Biotech Inc
MBRX
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$9.27
2.18
30.77%
Ult. Agg.: Oct 28, 5:25 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Moleculin Biotech Financials
Moleculin Biotech (MBRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Moleculin Biotech Q2 EPS $(1.40) Misses $(1.01) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.01) by 38.61 percent. This is a 88.57 percent increase over losses of $(12.25) per share
Benzinga Newsdesk
PRO
Moleculin Biotech Q1 EPS $(3.54) Misses $(1.57) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(3.54) per share which missed the analyst consensus estimate of $(1.57) by 125.48 percent. This is a 77.59 percent increase over losses of $(15.80) per share
Benzinga Newsdesk
PRO
Moleculin Biotech Q4 EPS $(26.06) Misses $(11.60) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(26.06) per share which missed the analyst consensus estimate of $(11.60) by 124.75 percent. This is a 181.73 percent decrease over losses of $(9.25) per
Benzinga Newsdesk
Nasdaq Surges 100 Points; Dollar General Earnings Beat Views
Avi Kapoor
US Stocks Mixed; Nvidia Posts Upbeat Earnings
Avi Kapoor
PRO
Moleculin Biotech Q2 EPS $(0.49) Misses $(0.42) Estimate
Moleculin Biotech (NASDAQ:MBRX) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate of $(0.42) by 16.67 percent. This is a 71.18 percent increase over losses of $(1.70) per share
Benzinga Newsdesk
